Cardiovascular diseases are a leading cause of death worldwide. There are various risk factors for cardiovascular disease such as obesity, physical inactivity, smoking, and diabetes. The risk of cardiovascular disease and stroke in patients with type 2 diabetes is more than twice that of people without diabetes.
Biomarkers can be used to improve risk stratification, a process that allows the identification of disease risk in order to minimize long-term complications and apply best therapies. There is a solid body of scientific data regarding the use of circulating stem cells as biomarkers for cardiovascular disease. For example, hematopoietic stem cell levels are decreased in people with an increased cardiovascular disease risk. Lower hematopoietic stem cell levels have been noted in patients with coronary artery disease and stroke. Therefore, a study was conducted to determine the role of CD34+CD133+ and CD34 stem cells in predicting cardiovascular outcomes in patients with diabetes.
The researchers of the study monitored a group of patients over a six year period. They recorded information regarding the time to a first cardiovascular crisis (stroke, heart attack, other heart-related hospitalization, and death). At the beginning of the study, the number of CD34+CD133 and CD34 stem cells was measured. Patients that experienced cardiovascular events were found to have lower levels of CD34+CD133 and CD34 stem cells than those without cardiovascular events. Patients with below average levels of CD34+CD133 or CD34 stem cells tended to have higher rates of cardiovascular crises.
Analysis of the data showed that the reduced CD34+CD133 or CD34 stem cell counts were predictive of future cardiovascular outcomes. Using both cell types improved the predictive ability. Lower levels of circulating CD34 stem cells in patients with type 2 diabetes predicted adverse cardiovascular outcomes up to 6 years after the beginning of the study. Using circulating stem cells as biomarkers of cardiovascular outcome in type 2 diabetes patients improves risk stratification for this population of patients.
At HemaCare, we understand the importance of top-notch, customizable cells for research in cardiovascular diseases. We offer CD34+ stem cells and CD133+ stem cells to meet your BioResearch needs. Order online or contact us at 877-397-3087 for further assistance.
Fadini, Gian Paolo et al. "Long-Term Prediction Of Cardiovascular Outcomes By Circulating CD34 + And CD34 + CD133 + Stem Cells In Patients With Type 2 Diabetes". http://care.diabetesjournals.org/content/40/1/125. N.p., 2017. Print.